Purpose: To describe a case of suspected tofacitinib-induced Vogt–Koyanagi–Harada (VKH)–like syndrome presenting with multifocal serous retinal detachments and choroidal involvement. Methods: A single case was reviewed. Results: A 66-year-old man with a history of vitiligo and vertigo presented with acute unilateral metamorphopsia. Clinical examination and multimodal imaging demonstrated multifocal serous retinal detachments with associated choroidal infiltration in the affected eye. The patient was monitored closely and experienced rapid resolution of symptoms and imaging abnormalities after discontinuation of tofacitinib. Conclusions: This case suggests a possible drug-induced VKH-like syndrome associated with tofacitinib use. Tofacitinib may be a potential risk factor for serous retinal detachment with choroidal involvement, warranting further investigation.
LeeEBFleischmannRHallS, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377-2386.
2.
SandbornWJSuCSandsBE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723-1736.
3.
SongHHuZZhangSYangLLiuYWangT. Effectiveness and safety of tofacitinib combined with narrowband ultraviolet B phototherapy for patients with refractory vitiligo in real-world clinical practice. Dermatol Ther. 2022;35(11):e15821.
4.
JamesHPaleyGLBrasingtonRCusterPLMargolisTPPaleyMA. Tofacitinib for refractory ocular mucous membrane pemphigoid. Am J Ophthalmol Case Rep. 2021;22:101104.
5.
PaleyMAKaracalHRaoPKMargolisTPMinerJJ. Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep. 2019;13:53-55.
6.
LiuXJiangQLvJ, et al. Insights gained from single-cell analysis of immune cells in tofacitinib treatment of Vogt-Koyanagi-Harada disease. JCI Insight. 2022;7(23):e162335.
7.
HecquetSValnet RabierM-BLepelleyM, et al. Ophthalmic adverse events under tofacitinib and baricitinib: case analysis of the European Pharmacovigilance Database. Joint Bone Spine. 2023;90(1):105483.
8.
CohenSBTanakaYMarietteX, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76(7):1253-1262.
9.
YtterbergSRBhattDLMikulsTR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316-326.
BricoutMPetreAAmini-AdleM, et al. Vogt-Koyanagi-Harada-like syndrome complicating pembrolizumab treatment for metastatic melanoma. J Immunother. 2017;40(2):77-82.
12.
ModoratiGMatteoDFMiserocchiEColucciABandelloF. Serous retinal detachments complicating interferon-α and ribavirin treatment in patients with hepatitis C. Case Rep Ophthalmol. 2011;2(1):105-110.
13.
YehSKarneNKKerkarSP, et al. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology. 2009;116(5):981-989.e981.
14.
WongRKLeeJKHuangJJ. Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of vogt-koyanagi-harada syndrome. Retin Cases Brief Rep. 2012;6(4):423-426.
15.
BoothAECHopkinsAMRowlandAKichenadasseGSmithJRSorichMJ. Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy. Ther Adv Med Oncol. 2020;12:1758835920944359.
16.
ZavoritiAMiossecP. Understanding cardiovascular events with JAK inhibitors: tofacitinib reduces synovial and vascular inflammation but not the prothrombotic effects of inflammatory cytokines on endothelium. ACR Open Rheumatol. 2025;7(1):e11790.
17.
BianchiJINirwanRSFulda GraueE, et al. Spontaneous resolution of a choroidal mass: a case series. Ocul Oncol Pathol. 2020;6(5):305-310.
18.
DreyerWBJrZegarraHZakovZNGutmanFA. Sympathetic ophthalmia. Am J Ophthalmol. 1981;92(6):816-823.
19.
RaoNAMarakGE. Sympathetic ophthalmia simulating vogt-Koyanagi-Harada’s disease: a clinico-pathologic study of four cases. Jpn J Ophthalmol. 1983;27(3):506-511.
